Company Profile

Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that may help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.

Anticalin proteins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins can virtually bind to any target of interest.

Pieris has a diverse pipeline of Anticalin Therapeutics for a number of different indications and has active, multi-program R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila and Stelis Biopharma.

Pieris, founded in 2001, was funded by premier biotechnology-focused venture capital firms including OrbiMed Advisors as its lead investor as well as Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, Global Life Science Ventures, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.

Pieris Pharmaceuticals, Inc.

Investor Presentation

Pieris Pharmaceuticals, Inc.

Fact Sheet

Pieris Pharmaceuticals, Inc.

2015 Annual Report

Pieris Pharmaceuticals, Inc.

Proxy Statement


Stock Snapshot

PIRS Symbol
Market Cap

Upcoming Events

PEGS, Protein and Antibody Engineering Summit Europe

Lisbon, Spain

View IR Calendar »